The current curative multimodal treatment of advanced esophageal cancers includes neoadjuvant or perioperative chemo(radio)therapy and radical surgical resection with a 2- or 3-field lymphadenectomy. Lymph node involvement is a significant predictor of long-term survival in esophageal cancer patients. The distribution pattern of lymph node metastases is unpredictable and depends on various factors. The extent of lymphadenectomy remains controversial, with some advocating for aggressive and extended dissection while others support a more restricted approach. This review provides an overview of the development and current evidence for lymphadenectomy in esophageal cancer treatment.
Journal Article by Schuring N, van Berge Henegouwen MI and Gisbertz SS in Dis Esophagus
© The Author(s) 2023. Published by Oxford University Press on behalf of International Society for Diseases of the Esophagus.